Abstract
Most xenobiotics do not remain unchanged in the human organism (and in other organisms), but rather are metabolized. The change in chemical characteristics of the thereby produced metabolites as compared with the chemical characteristics of the corresponding parent compounds usually leads to changes in both the desired properties, e.g., therapeutic efficacy, and also in undesired properties, i.e., xenobiotic metabolism usually is toxicologically not neutral, but rather leads in most cases to toxication or detoxication of the respective compound (overview see Oesch-Bartlomowicz and Oesch 2007). Thereby xenobiotic metabolism becomes one of the most important factors controlling the toxicity of the respective compound. This, in turn, makes xenobiotic-metabolizing enzymes to control factors for xenobiotic toxicity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arand M, Oesch F (2004) Fremdstoffmetabolismus. In: Marquardt H, Schäfer S (eds) Lehrbuch der Toxikologie. Wissenschaftliche Verlagsanstalt Stuttgart, Germany, pp 89–116
Back DJ, Grimmer SF, Orme ML, Proudlove C, Mann RD, Breckenridge AM (1988) Evaluation of committee on safety of medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 25:527–532
Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human-cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152
Cole KE, Jones TW, Lipsky MM, Trump BF, Hsu IC (1988) In vitro binding of aflatoxin B1 and 2-acetylaminofluorene to rat, mouse and human hepatocyte DNA: the relationship of DNA binding to carcinogenicity. Carcinogenesis 9:711–716
Davis CD, Adamson RH, Snyderwine EG (1993) Studies on the mutagenic activation of heterocyclic amines by cynomolgus monkey, rat and human microsomes show that cynomolgus monkeys have a low capacity to N-oxidize the quinoxaline-type heterocyclic amines. Cancer Lett 73:95–104
Hengstler JG, Oesch F (1999) Interspecies differences in xenobiotic metabolizing enzymes and their importance for interspecies extrapolation of toxicity. In: Ballantyne B, Marrs TC, Syversen T (eds) General and applied toxicology. Macmillan, London, pp 271–290
Hengstler JG, van der Burg B, Steinberg P, Oesch F (1999) Interspecies differences in cancer susceptibility and toxicology. Drug Metab Rev 31:917–970
Hengstler JG, Bogdanffy MS, Bolt HM, Oesch F (2003) Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate. Annu Rev Pharmacol Toxicol 43:485–520
Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS (1995) Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 23:415–421
Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ (2007) The pregnane X receptor gene humanized mouse: a model for investigating drug–drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194–200
Martignoni M, Groothuis GM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894
McLean AE, McLean EK (1966) The effect of diet and 1,1,1-trichloro-2,2-bis-(p-chlorophenyl)ethane (DDT) on microsomal hydroxylating enzymes and on sensitivity of rats to carbon tetrachloride poisoning. Biochem J 100:564–571
Modak AS (2010) Single time point diagnostic breath tests: a review. J Breath Res 4:1–6
Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, Francke-Carroll S (2010) Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. Toxicol Pathol 38:799–809
Oesch F, Arand M (1999) Xenobiotic metabolism. In: Marquardt H, Schäfer S, McLellan D, Welsch C (eds) Toxicology. Academic, San Diego, pp 84–110
Oesch-Bartlomowicz B, Oesch F (2007) Mechanisms of toxication and detoxication which challenge drug candidates and drugs. In: Triggle D, Taylor J (eds) Comprehensive medicinal medicine. Elsevier, Philadelphia, pp 193–214
Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N, Wolf CR (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228–3239
Schroeder K, Bremm KD, Alépée N, Bessems JG, Blaauboer B, Boehn SN, Burek C, Coecke S, Gombau L, Hewitt NJ, Heylings J, Huwyler J, Jaeger M, Jagelavicius M, Jarrett N, Ketelslegers H, Kocina I, Koester J, Kreysa J, Note R, Poth A, Radtke M, Rogiers V, Scheel J, Schulz T, Steinkellner H, Toeroek M, Whelan M, Winkler P, Diembeck W (2011) Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors. Toxicol In Vitro 25:589–604
Slone DH, Gallagher EP, Ramsdell HS, Rettie AE, Stapleton PL, Berlad LG, Eaton DL (1995) Human variability in hepatic glutathione S-transferase-mediated conjugation of aflatoxin B1-epoxide and other chemicals. Pharmacogenetics 5:224–233
U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER) (2008) Safety testing of drug metabolites. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. Accessed November 2009
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208
Wilson AS, Williams DP, Davis CD, Tingle MD, Park BK (1997) Bioactivation and inactivation of aflatoxin B1 by human, mouse and rat liver preparations: effect on SCE in human mononuclear leucocytes. Mutat Res 373:257–264
Zuber R, Anzenbacherova E, Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–198
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Oesch, F., Hengstler, J.G. (2014). Importance of Metabolism. Mechanistic Considerations Relevant for Toxicological Regulation. In: Reichl, FX., Schwenk, M. (eds) Regulatory Toxicology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35374-1_71
Download citation
DOI: https://doi.org/10.1007/978-3-642-35374-1_71
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35373-4
Online ISBN: 978-3-642-35374-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences